September 2021 | Targeted Therapies in Oncology

Venetoclax Plus R2 Is Safe and Effective in Frontline MCL

September 28, 2021

Clinical Articles

According to Tycel Jovelle Phillips, MD, the study of venetoclax in combination with the R2 regimen will be expanded to include 50 patients with mantle cell lymphoma without a TP53 mutation.

Early-Phase Targeted Agents Are Poised to Expand Armamentarium in HNSCC

September 23, 2021

Clinical Articles

The emergence of early-phase immune-oncology agents and their respective novel mechanisms of action in head and neck squamous cell carcinoma suggests a new standard of care in the metastatic first-line setting within the next 2 years.

Targeted Agents, Immunotherapies Are Advancing to the Adjuvant Setting in Solid Tumors

September 20, 2021

Clinical Articles

After success in malignant melanoma and non–small cell lung cancer, adjuvant treatments are demonstrating improvements in disease-free survival in other cancers, including renal cell carcinoma, esophageal/gastroesophageal cancer, and breast cancer.